Global Veterinary Viral Vectored Vaccine 麻豆原创 Growth 2025-2031

Publication ID:

LPI02253424

Publication Date:

February 27, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Veterinary Viral Vectored Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from 拢2.6bn in 2015 to 拢4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China"s Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China"s pet medical market is about 楼67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 551%.
The 鈥淰eterinary Viral Vectored Vaccine Industry Forecast鈥� looks at past sales and reviews total world Veterinary Viral Vectored Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Veterinary Viral Vectored Vaccine sales for 2025 through 2031. With Veterinary Viral Vectored Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Veterinary Viral Vectored Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Veterinary Viral Vectored Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Veterinary Viral Vectored Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Veterinary Viral Vectored Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Veterinary Viral Vectored Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Veterinary Viral Vectored Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Veterinary Viral Vectored Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Alphaherpesvirus (HVT) Vector
Canarypox Vector
Vaccinia Vector
Segmentation by Application:
Pet
Chicken
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Boehringer-Ingelheim
Ceva
Key Questions Addressed in this Report
What is the 10-year outlook for the global Veterinary Viral Vectored Vaccine market?
What factors are driving Veterinary Viral Vectored Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Veterinary Viral Vectored Vaccine market opportunities vary by end market size?
How does Veterinary Viral Vectored Vaccine break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Veterinary Viral Vectored Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Veterinary Viral Vectored Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Veterinary Viral Vectored Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Veterinary Viral Vectored Vaccine Segment by Type
2.2.1 Alphaherpesvirus (HVT) Vector
2.2.2 Canarypox Vector
2.2.3 Vaccinia Vector
2.3 Veterinary Viral Vectored Vaccine Sales by Type
2.3.1 Global Veterinary Viral Vectored Vaccine Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Veterinary Viral Vectored Vaccine Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Veterinary Viral Vectored Vaccine Sale Price by Type (2020-2025)
2.4 Veterinary Viral Vectored Vaccine Segment by Application
2.4.1 Pet
2.4.2 Chicken
2.4.3 Others
2.5 Veterinary Viral Vectored Vaccine Sales by Application
2.5.1 Global Veterinary Viral Vectored Vaccine Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Veterinary Viral Vectored Vaccine Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Veterinary Viral Vectored Vaccine Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Veterinary Viral Vectored Vaccine Breakdown Data by Company
3.1.1 Global Veterinary Viral Vectored Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Veterinary Viral Vectored Vaccine Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Veterinary Viral Vectored Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Veterinary Viral Vectored Vaccine Revenue by Company (2020-2025)
3.2.2 Global Veterinary Viral Vectored Vaccine Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Veterinary Viral Vectored Vaccine Sale Price by Company
3.4 Key Manufacturers Veterinary Viral Vectored Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Veterinary Viral Vectored Vaccine Product Location Distribution
3.4.2 Players Veterinary Viral Vectored Vaccine Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Veterinary Viral Vectored Vaccine by Geographic Region
4.1 World Historic Veterinary Viral Vectored Vaccine 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Veterinary Viral Vectored Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Veterinary Viral Vectored Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Veterinary Viral Vectored Vaccine 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Veterinary Viral Vectored Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Veterinary Viral Vectored Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Veterinary Viral Vectored Vaccine Sales Growth
4.4 APAC Veterinary Viral Vectored Vaccine Sales Growth
4.5 Europe Veterinary Viral Vectored Vaccine Sales Growth
4.6 Middle East & Africa Veterinary Viral Vectored Vaccine Sales Growth
5 Americas
5.1 Americas Veterinary Viral Vectored Vaccine Sales by Country
5.1.1 Americas Veterinary Viral Vectored Vaccine Sales by Country (2020-2025)
5.1.2 Americas Veterinary Viral Vectored Vaccine Revenue by Country (2020-2025)
5.2 Americas Veterinary Viral Vectored Vaccine Sales by Type (2020-2025)
5.3 Americas Veterinary Viral Vectored Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Veterinary Viral Vectored Vaccine Sales by Region
6.1.1 APAC Veterinary Viral Vectored Vaccine Sales by Region (2020-2025)
6.1.2 APAC Veterinary Viral Vectored Vaccine Revenue by Region (2020-2025)
6.2 APAC Veterinary Viral Vectored Vaccine Sales by Type (2020-2025)
6.3 APAC Veterinary Viral Vectored Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Veterinary Viral Vectored Vaccine by Country
7.1.1 Europe Veterinary Viral Vectored Vaccine Sales by Country (2020-2025)
7.1.2 Europe Veterinary Viral Vectored Vaccine Revenue by Country (2020-2025)
7.2 Europe Veterinary Viral Vectored Vaccine Sales by Type (2020-2025)
7.3 Europe Veterinary Viral Vectored Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Veterinary Viral Vectored Vaccine by Country
8.1.1 Middle East & Africa Veterinary Viral Vectored Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Veterinary Viral Vectored Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Veterinary Viral Vectored Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Veterinary Viral Vectored Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Veterinary Viral Vectored Vaccine
10.3 Manufacturing Process Analysis of Veterinary Viral Vectored Vaccine
10.4 Industry Chain Structure of Veterinary Viral Vectored Vaccine
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Veterinary Viral Vectored Vaccine Distributors
11.3 Veterinary Viral Vectored Vaccine Customer
12 World Forecast Review for Veterinary Viral Vectored Vaccine by Geographic Region
12.1 Global Veterinary Viral Vectored Vaccine 麻豆原创 Size Forecast by Region
12.1.1 Global Veterinary Viral Vectored Vaccine Forecast by Region (2026-2031)
12.1.2 Global Veterinary Viral Vectored Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Veterinary Viral Vectored Vaccine Forecast by Type (2026-2031)
12.7 Global Veterinary Viral Vectored Vaccine Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Boehringer-Ingelheim
13.1.1 Boehringer-Ingelheim Company Information
13.1.2 Boehringer-Ingelheim Veterinary Viral Vectored Vaccine Product Portfolios and Specifications
13.1.3 Boehringer-Ingelheim Veterinary Viral Vectored Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Boehringer-Ingelheim Main Business Overview
13.1.5 Boehringer-Ingelheim Latest Developments
13.2 Ceva
13.2.1 Ceva Company Information
13.2.2 Ceva Veterinary Viral Vectored Vaccine Product Portfolios and Specifications
13.2.3 Ceva Veterinary Viral Vectored Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Ceva Main Business Overview
13.2.5 Ceva Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.